Cytosporone B, an inhibitor of the type III secretion system of Salmonella enterica serovar typhimurium

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 5, 2013, Pages 2191-2198

  Li, Jianfang ^a,b   Lv, Chao ^a   Sun, Weiyang ^b   Li, Zhenyu ^a   Han, Xiaowei ^a   Li, Yaoyao ^a   Shen, Yuemao ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CYTOSPORONE B; HISTONE LIKE NUCLEOID STRUCTURING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL VIRULENCE; CONTROLLED STUDY; DRUG INHIBITION; FLAGELLUM; GENE EXPRESSION; HELA CELL; IN VITRO STUDY; NONHUMAN; PATHOGENICITY ISLAND; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; TYPE III SECRETION SYSTEM;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; GENE EXPRESSION REGULATION, BACTERIAL; GENOMIC ISLANDS; HELA CELLS; HUMANS; PHENYLACETATES; PROMOTER REGIONS, GENETIC; SALMONELLA TYPHIMURIUM; TRANSCRIPTION FACTORS; VIRULENCE FACTORS;

EID: 84876247610     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02421-12     Document Type: Article

References (63)

1. Aiello D, Williams JD, Majgier-Baranowska H, Patel I, Peet NP, Huang J, Lory S, Bowlin TL, Moir DT. 2010. Discovery and characterization of inhibitors of Pseudomonas aeruginosa type III secretion. Antimicrob. Agents Chemother. 54:1988-1999.
2. Kimura K, Iwatsuki M, Nagai T, Matsumoto A, Takahashi Y, Shiomi K, Omura S, Abe A. 2011. A small-molecule inhibitor of the bacterial type III secretion system protects against in vivo infection with Citrobacter rodentium. J. Antibiot. 64:197-203.
3. Stamm LM, Goldberg MB. 2011. Microbiology. Establishing the secretion hierarchy. Science 331:1147-1148.
4. Marlovits TC, Stebbins CE. 2010. Type III secretion systems shape up as they ship out. Curr. Opin. Microbiol. 13:47-52.
5. Worrall LJ, Lameignere E, Strynadka NC. 2011. Structural overview of the bacterial injectisome. Curr. Opin. Microbiol. 14:3-8.
6. Hueck CJ. 1998. Type III protein secretion systems in bacterial pathogens of animals and plants. Microbiol. Mol. Biol. Rev. 62:379-433.
7. Sun GW, Gan YH. 2010. Unraveling type III secretion systems in the highly versatile Burkholderia pseudomallei. Trends Microbiol. 18:561-568.
8. Macnab RM. 2003. How bacteria assemble flagella. Annu. Rev. Microbiol. 57:77-100.
9. Tampakaki AP, Fadouloglou VE, Gazi AD, Panopoulos NJ, Kokkinidis M. 2004. Conserved features of type III secretion. Cell.Microbiol. 6:805-816.
10. Blocker A, Komoriya K, Aizawa S. 2003. Type III secretion systems and bacterial flagella: insights into their function from structural similarities. Proc. Natl. Acad. Sci. U. S. A. 100:3027-3030.
11. Layton AN, Hudson DL, Thompson A, Hinton JC, Stevens JM, Galyov EE, Stevens MP. 2010. Salicylidene acylhydrazide-mediated inhibition of type III secretion system-1 in Salmonella enterica serovar Typhimurium is associated with iron restriction and can be reversed by free iron. FEMS Microbiol. Lett. 302:114-122.
12. Patel JC, Rossanese OW, Galan JE. 2005. The functional interface between Salmonella and its host cell: opportunities for therapeutic intervention. Trends Pharmacol. Sci. 26:564-570.
13. Keyser P, Elofsson M, Rosell S, Wolf-Watz H. 2008. Virulence blockers as alternatives to antibiotics: type III secretion inhibitors against Gramnegative bacteria. J. Intern. Med. 264:17-29.
14. Nordfelth R, Kauppi AM, Norberg HA, Wolf-Watz H, Elofsson M. 2005. Small-molecule inhibitors specifically targeting type III secretion. Infect. Immun. 73:3104-3114.
15. Swietnicki W, Carmany D, Retford M, Guelta M, Dorsey R, Bozue J, Lee MS, Olson MA. 2011. Identification of small-molecule inhibitors of Yersinia pestis type III secretion system YscN ATPase. PLoS One 6:e19716. doi:10.1371/journal. pone.0019716.
16. Crabill E, Joe A, Block A, van Rooyen JM, Alfano Jr. 2010. Plant immunity directly or indirectly restricts the injection of type III effectors by the Pseudomonas syringae type III secretion system. Plant Physiol. 154:233-244.
17. Gauthier A, Finlay BB. 2002. Type III secretion system inhibitors are potential antimicrobials. ASM News 68:383-387.
18. Marra A. 2006. Targeting virulence for antibacterial chemotherapy: identifying and characterising virulence factors for lead discovery. Drugs R. D. 7:1-16.
19. Kauppi AM, Andersson CD, Norberg HA, Sundin C, Linusson A, Elofsson M. 2007. Inhibitors of type III secretion in Yersinia: design, synthesis and multivariate QSAR of 2-arylsulfonylamino-benzanilides. Bioorg. Med. Chem. 15:6994-7011.
20. Gauthier A, Robertson ML, Lowden M, Ibarra JA, Puente JL, Finlay BB. 2005. Transcriptional inhibitor of virulence factors in enteropathogenic Escherichia coli. Antimicrob. Agents Chemother. 49:4101-4109.
21. Pan NJ, Brady MJ, Leong JM, Goguen JD. 2009. Targeting type III secretion in Yersinia pestis. Antimicrob. Agents Chemother. 53:385-392.
22. Miki T, Okada N, Shimada Y, Danbara H. 2004. Characterization of Salmonella pathogenicity island 1 type III secretion-dependent hemolytic activity in Salmonella enterica serovar Typhimurium. Microb. Pathog. 37:65-72.
23. Linington RG, Robertson M, Gauthier A, Finlay BB, MacMillan JB, Molinski TF, van Soest R, Andersen RJ. 2006. Caminosides B-D, antimicrobial glycolipids isolated from the marine sponge Caminus sphaeroconia. J. Nat. Prod. 69:173-177.
24. Linington RG, Robertson M, Gauthier A, Finlay BB, van Soest R, Andersen RJ. 2002. Caminoside A, an antimicrobial glycolipid isolated from the marine sponge Caminus sphaeroconia. Org. Lett. 4:4089-4092.
25. Kauppi AM, Nordfelth R, Uvell H, Wolf-Watz H, Elofsson M. 2003. Targeting bacterial virulence: inhibitors of type III secretion in Yersinia. Chem. Biol. 10:241-249.
26. Kauppi AM, Nordfelth R, Hagglund U, Wolf-Watz H, Elofsson M. 2003. Salicylanilides are potent inhibitors of type III secretion in Yersinia. Adv. Exp. Med. Biol. 529:97-100.
27. Dahlgren MK, Zetterstrom CE, Gylfe S, Linusson A, Elofsson M. 2010. Statistical molecular design of a focused salicylidene acylhydrazide library and multivariate QSAR of inhibition of type III secretion in the Gramnegative bacterium Yersinia. Bioorg. Med. Chem. 18:2686-2703.
28. Muschiol S, Bailey L, Gylfe A, Sundin C, Hultenby K, Bergstrom S, Elofsson M, Wolf-Watz H, Normark S, Henriques-Normark B. 2006. A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis. Proc. Natl. Acad. Sci. U. S. A. 103:14566-14571.
29. Wolf K, Betts HJ, Chellas-Gery B, Hower S, Linton CN, Fields KA. 2006. Treatment of Chlamydia trachomatis with a small molecule inhibitor of the Yersinia type III secretion system disrupts progression of the chlamydial developmental cycle. Mol. Microbiol. 61:1543-1555.
30. Bailey L, Gylfe A, Sundin C, Muschiol S, Elofsson M, Nordstrom P, Henriques-Normark B, Lugert R, Waldenstrom A, Wolf-Watz H, Bergstrom S. 2007. Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle. FEBS Lett. 581:587-595.
31. Slepenkin A, Enquist PA, Hagglund U, de la Maza LM, Elofsson M, Peterson EM. 2007. Reversal of the antichlamydial activity of putative type III secretion inhibitors by iron. Infect. Immun. 75:3478-3489.
32. Chu H, Slepenkin A, Elofsson M, Keyser P, de la Maza LM, Peterson EM. 2010. Candidate vaginal microbicides with activity against Chlamydia trachomatis and Neisseria gonorrhoeae. Int. J. Antimicrob. Agents 36:145-150.
33. Muschiol S, Normark S, Henriques-Normark B, Subtil A. 2009. Small molecule inhibitors of the Yersinia type III secretion system impair the development of Chlamydia after entry into host cells. BMC Microbiol. 9:75.
34. Slepenkin A, Chu H, Elofsson M, Keyser P, Peterson EM. 2011. Protection of mice from a Chlamydia trachomatis vaginal infection using a salicylidene acylhydrazide, a potential microbicide. J. Infect. Dis. 204: 1313-1320.
35. Yount JS, Tsou LK, Dossa PD, Kullas AL, van der Velden AW, Hang HC. 2010. Visible fluorescence detection of type III protein secretion from bacterial pathogens. J. Am. Chem. Soc. 132:8244-8245.
36. Hudson DL, Layton AN, Field TR, Bowen AJ, Wolf-Watz H, Elofsson M, Stevens MP, Galyov EE. 2007. Inhibition of type III secretion in Salmonella enterica serovar Typhimurium by small-molecule inhibitors. Antimicrob. Agents Chemother. 51:2631-2635.
37. Negrea A, Bjur E, Ygberg SE, Elofsson M, Wolf-Watz H, Rhen M. 2007. Salicylidene acylhydrazides that affect type III protein secretion in Salmonella enterica serovar Typhimurium. Antimicrob. Agents Chemother. 51: 2867-2876.
38. Veenendaal AK, Sundin C, Blocker AJ. 2009. Small-molecule type III secretion system inhibitors block assembly of the Shigella type III secreton. J. Bacteriol. 191:563-570.
39. Tree JJ, Wang D, McInally C, Mahajan A, Layton A, Houghton I, Elofsson M, Stevens MP, Gally DL, Roe AJ. 2009. Characterization of the effects of salicylidene acylhydrazide compounds on type III secretion in Escherichia coli O157:H7. Infect. Immun. 77:4209-4220.
40. Dahlgren MK, Kauppi AM, Olsson I-M, Linusson A, Elofsson M. 2007. Design, synthesis, and multivariate quantitative structure-activity relationship of salicylanilides - potent inhibitors of type III secretion in Yersinia. J. Med. Chem. 50:6177-6188.
41. Baron C. 2010. Antivirulence drugs to target bacterial secretion systems. Curr. Opin. Microbiol. 13:100-105.
42. Felise HB, Nguyen HV, Pfuetzner RA, Barry KC, Jackson SR, Blanc MP, Bronstein PA, Kline T, Miller SI. 2008. An inhibitor of gram-negative bacterial virulence protein secretion. Cell Host Microbe 4:325-336.
43. Li Y, Peng Q, Selimi D, Wang Q, Charkowski AO, Chen X, Yang CH. 2009. The plant phenolic compound p-coumaric acid represses gene expression in the Dickeya dadantii type III secretion system. Appl. Environ. Microbiol. 75:1223-1228.
44. Yamazaki A, Li J, Zeng Q, Khokhani D, Hutchins WC, Yost AC, Biddle E, Toone EJ, Chen X, Yang CH. 2012. Derivatives of plant phenolic compound affect the type III secretion system of Pseudomonas aeruginosa via a GacS-GacA two-component signal transduction system. Antimicrob. Agents Chemother. 56:36-43.
45. Bhan MK, Bahl R, Bhatnagar S. 2005. Typhoid and paratyphoid fever. Lancet 366:749-762.
46. Hensel M. 2004. Evolution of pathogenicity islands of Salmonella enterica. Int. J. Med. Microbiol. 294:95-102.
47. Curtiss R, III, Wanda S-Y, Gunn BM, Zhang X, Tinge SA, Ananthnarayan V, Mo H, Wang S, Kong W. 2009. Salmonella enterica serovar Typhimurium strains with regulated delayed attenuation in vivo. Infect. Immun. 77:1071-1082.
48. Preet R, Mohapatra P, Mohanty S, Sahu SK, Choudhuri T, Wyatt MD, Kundu CN. 2012. Quinacrine has anticancer activity in breast cancer cells through inhibition of topoisomerase activity. Int. J. Cancer 130:1660-1670.
49. Schmittgen TD, Livak KJ. 2008. Analyzing real-time PCR data by the comparative CT method. Nat. Protoc. 3:1101-1108.
50. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc. Natl. Acad. Sci. U. S. A. 97:6640-6645.
51. Wang RF, Kushner SR. 1991. Construction of versatile low-copynumber vectors for cloning, sequencing and gene expression in Escherichia coli. Gene 100:195-199.
52. Brady SF, Wagenaar MM, Singh MP, Janso JE, Clardy J. 2000. The cytosporones, new octaketide antibiotics isolated from an endophytic fungus. Org. Lett. 2:4043-4046.
53. Zhan Y, Du X, Chen H, Liu J, Zhao B, Huang D, Li G, Xu Q, Zhang M, Weimer BC, Chen D, Cheng Z, Zhang L, Li Q, Li S, Zheng Z, Song S, Huang Y, Ye Z, Su W, Lin SC, Shen Y, Wu Q. 2008. Cytosporone B is an agonist for nuclear orphan receptor Nur77. Nat. Chem. Biol. 4:548-556.
54. Mizusaki H, Takaya A, Yamamoto T, Aizawa S. 2008. Signal pathway in salt-activated expression of the Salmonella pathogenicity island 1 type III secretion system in Salmonella enterica serovar Typhimurium. J. Bacteriol. 190:4624-4631.
55. Bueno SM, Wozniak A, Leiva ED, Riquelme SA, Carreno LJ, Hardt WD, Riedel CA, Kalergis AM. 2010. Salmonella pathogenicity island 1 differentially modulates bacterial entry to dendritic and non-phagocytic cells. Immunology 130:273-287.
56. Collazo CM, Galan JE. 1996. Requirement for exported proteins in se- cretion through the invasion-associated type III system of Salmonella typhimurium. Infect. Immun. 64:3524-3531.
57. Golubeva YA, Sadik AY, Ellermeier JR, Slauch JM. 2012. Integrating global regulatory input into the Salmonella pathogenicity island 1 type III secretion system. Genetics 190:79-90.
58. Ellermeier CD, Ellermeier JR, Slauch JM. 2005. HilD, HilC and RtsA constitute a feed forward loop that controls expression of the SPI1 type three secretion system regulator hilA in Salmonella enterica serovar Typhimurium. Mol. Microbiol. 57:691-705.
59. Olekhnovich IN, Kadner RJ. 2007. Role of nucleoid-associated proteins Hha and H-NS in expression of Salmonella enterica activators HilD, HilC, and RtsA required for cell invasion. J. Bacteriol. 189:6882-6890.
60. Aguirre A, Cabeza ML, Spinelli SV, McClelland M, Garcia Vescovi E, Soncini FC. 2006. PhoP-induced genes within Salmonella pathogenicity island 1. J. Bacteriol. 188:6889-6898.
61. Queiroz MH, Madrid C, Paytubi S, Balsalobre C, Juarez A. 2011. Integration host factor alleviates H-NS silencing of the Salmonella enterica serovar Typhimurium master regulator of SPI1, hilA. Microbiology 157:2504-2514.
62. De Alba CF, Solorzano C, Paytubi S, Madrid C, Juarez A, Garcia J, Pons M. 2011. Essential residues in the H-NS binding site of Hha, a co-regulator of horizontally acquired genes in Enterobacteria. FEBS Lett. 585:1765-1770.
63. Ono S, Goldberg MD, Olsson T, Esposito D, Hinton JC, Ladbury JE. 2005. H-NS is a part of a thermally controlled mechanism for bacterial gene regulation. Biochem. J. 391:203-213.